EGFR and autosomal dominant polycystic kidney disease: Although the response of renal cyst of VHL disease to TKIs has not been reported in previous research, we found that some TKIs were used to treat autosomal-dominant polycystic kidney disease (ADPDK) in previous literature; the research considered that TKIs can be used to decrease EGFR tyrosine kinase activity and collecting tubule cyst formation and enlargement in polycystic kidney disease (29, 30).